Improving medication therapy management through collaborative hospice care in rural Minnesota

2010 ◽  
Vol 50 (3) ◽  
pp. 379-383 ◽  
Author(s):  
Karla P. Eischens ◽  
Sheila W.C. Gilling ◽  
Ryan E. Okerlund ◽  
Teresa R. Grund ◽  
Paul S. Iverson ◽  
...  
Keyword(s):  
Hospice Care ◽  
Medication Therapy Management ◽  
Therapy Management ◽  
Medication Therapy

Implementation and Clinical Outcomes of an Employer-Sponsored, Pharmacist-Provided Medication Therapy Management Program

2015 ◽  
Vol 35 (11) ◽  
pp. e159-e163 ◽  
Author(s):  
Katie M. Theising ◽  
Traci L. Fritschle ◽  
Angelina M. Scholfield ◽  
Emily L. Hicks ◽  
Michelle L. Schymik
Keyword(s):  
Clinical Outcomes ◽  
Management Program ◽  
Medication Therapy Management ◽  
Therapy Management ◽  
Medication Therapy

scholarly journals Should Eligibility for Medication Therapy Management Be Based on Drug Adherence?

2014 ◽  
Vol 20 (1) ◽  
pp. 66-76 ◽  
Author(s):  
Bruce Stuart ◽  
Ellen Loh ◽  
Laura Miller ◽  
Pamela Roberto
Keyword(s):  
Medication Therapy Management ◽  
Drug Adherence ◽  
Therapy Management ◽  
Medication Therapy

Pharmacist-provided medication therapy management (part 2): Payer perspectives in 2007

2008 ◽  
Vol 48 (4) ◽  
pp. 478-486 ◽  
Author(s):  
Jon C. schommer ◽  
Lourdes G. Planas ◽  
Kathleen A Johnson ◽  
William R. Doucette
Keyword(s):  
Medication Therapy Management ◽  
Therapy Management ◽  
Medication Therapy

Abstract P12: Medication Therapy Management Services - A Requirement for Medicare Part D Plans: Are Your Patients Eligible?

2011 ◽  
Vol 4 (suppl_2) ◽  
Author(s):  
Sarah A Spinler ◽  
Mark J Cziraky ◽  
Paul S Chan ◽  
Feng-ming Tang ◽  
Gladys G Duenas ◽  
...  
Keyword(s):  
Drug Cost ◽  
Average Cost ◽  
Medicare Part D ◽  
Medication Therapy Management ◽  
Drug Costs ◽  
Medicare Part ◽  
Cardiac Diseases ◽  
Part D ◽  
Therapy Management ◽  
Medication Therapy

Background: Medication Therapy Management (MTM) is a mandated component of Medicare Part D whereby a pharmacist-patient encounter identifies, resolves and prevents medication-related problems. MTM programs have been shown to improve drug therapy goal attainment while reducing overall costs in cardiac patients; however, MTM has been greatly underutilized. The purpose of this study is to identify the proportion of patients eligible for MTM from those enrolled in the NCDR's outpatient PINNACLE Registry. Methods: MTM eligibility is based on the presence of multiple chronic diseases and medications plus the likelihood of exceeding an annual drug cost threshold ($4000 in 2009 and $3000 in 2010). Patients from PINNACLE (5/1/08 to 9/30/10) with 3 or more of the following diseases were identified: HTN, HF, dyslipidemia, DM, CAD. Patient demographics, cardiac diseases, and cardiac drug classes prescribed (individual drugs not available) were captured. To estimate individual patient drug costs to determine MTM eligibility, a weighted average cost was calculated using nationally representative drug utilization data and average wholesale prices (AWP). Sensitivity analyses for determining MTM eligibility were performed by varying drug costs using AWP for the highest cost and clinician-defined most frequently prescribed drugs in each class. Results: Of the 160,593 Medicare patients enrolled in PINNACLE, 93,089 (58%) were identified with ≥ 3 cardiac diseases. The cohort’s mean age was 74.4 ± 9.2 yrs, 54.4% were male and 86.5% were white. Patients were prescribed a mean of 3.5 cardiac drugs. The table displays drug costs and MTM eligibility results. Conclusions: A substantial number of patients met MTM eligibility requirements with this conservative approach using only cardiac drug costs, although variability existed based on cost method. These data serve to raise cardiologists' awareness of their patients' potential eligibility to receive the benefits of MTM services. Cost Methodology Median Annual Cost (IQR) 2009 MTM Eligibility [N (%)] 2010 MTM Eligibility [N (%)] Weighed average cost $1329 (915,2609) 6,202 (6.7% ) 19,903 (21.4%) Frequently prescribed cost $366 (193,1361) 1084 (1.2% ) 7326 (7.9%) High cost $3,958 (2406,5358) 46,477 (49.9% ) 59,619 (64%) 2009 and 2010 MTM eligibility based on likelihood of exceeding drug cost threshold of $4000 and $3000, respectively. IQR - interquartile range; MTM - medication therapy management.

Sign in / Sign up

Export Citation Format

Share Document